Empowering patient educators to increase awareness and decrease educational gap in #amyloidosis BU AMYLOIDOSIS CENTER Amyloidosis Speakers Bureau

Evaluating the Amyloidosis Speakers Bureau: the influence of amyloidosis patients' narratives on medical students' … pubmed.ncbi.nlm.nih.gov/37753389/

#IMS2023 It is a wrap up!

Stem cell transplant using Propylene glycol-free melphalan (Evomela) had low rates of renal toxicity in our BU AMYLOIDOSIS CENTER ph2 trial; a problem often associated w melphalan in AL amyloidosis pts w renal involvement.
#amyloidosis

sciencedirect.com/science/articl…

Meet the professors: AL amyloidosis #IMS2023 great attendance and a very interactive session awechalekar Vaishali Sanchorawala BU AMYLOIDOSIS CENTER

Phase II clinical trial results from BU AMYLOIDOSIS CENTER
Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem C… pubmed.ncbi.nlm.nih.gov/37607644/

Goodbye to Doxycycline in AL amyloidosis! BU AMYLOIDOSIS CENTER

The impact of Post-Transplant doxycycline in AL amyloidosis – updated results after Long-Term follow up: Amyloid: Vol 30, No 3 tandfonline.com/doi/abs/10.108…

pubmed.ncbi.nlm.nih.gov/34503349/

15 cases of AGelsolin amyloidosis: largest series in the US. 20% renal involvement, 7% cardiac involvement besides cranial, peripheral and autonomic neuropathy. Lisa Mendelson Vaishali Sanchorawala
pubmed.ncbi.nlm.nih.gov/37140928/

Just published! 142 patients with stage IIIb AL amyloidosis remains a heterogenous group but median OS 9 mos. BU AMYLOIDOSIS CENTER Josh Gustine
Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis ashpublications.org/bloodadvances/…

MiracleMab: Unleashing Hope with Birtamimab!
BU AMYLOIDOSIS CENTER
Birtamimab Plus Standard of Care in Patients With Newly Diagnosed Treatment-Naïve Light Chain Amyloidosis | comment: Vaishali Sanchorawala MD prac.co/l/256d89dk via PracticeUpdate

Lesson: Mistake to be on hem malignancy service before ASH abstract submission deadline! Lesson learnt the hard way! BU AMYLOIDOSIS CENTER BUHemeOncFellows

Neurologic manifestations of ATTRv amyloidosis: Of the 36 patients with V122I TTR mutation, over half
(19) had signs or symptoms attributable to polyneuropathy (without competing causes), eight of whom did not have cardiac involvement. BU AMYLOIDOSIS CENTER
pubmed.ncbi.nlm.nih.gov/35253562/

Unique transcriptional- and chromatin level signatures of TTR-and LC-mediated destabilized protein, representing cellular responses to aggregation-prone proteins and ER stress BU AMYLOIDOSIS CENTER CReM George J. Murphy Rich Giadone

tandfonline.com/doi/full/10.10…

Ground breaking results for patients with #amyloidosis and looking forward to future clinical trials BU AMYLOIDOSIS CENTER

Improvement in time to ACM with birtamimab at month 9; Survival at month 9 for Mayo 2012 stage IV - 74% with birtamimab and 49% for placebo
Birtamimab plus standard of care in light chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial pubmed.ncbi.nlm.nih.gov/37366170/

Basis for AFFIRM-AL trial. Enroll patients on this trial of antifibril antibody for AL amyloidosis. BU AMYLOIDOSIS CENTER
Birtamimab plus standard of care in light chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial ashpublications.org/blood/article/…

Topic dear to my heart! #AmyloidosisForum Moderated by Dr Feredrick Ruberg Frederick L Ruberg of BU AMYLOIDOSIS CENTER Amyloidosis Research Consortium

Avoid implicit bias in amyloidosis & never skip genetic testing, particularly in minority groups. At BU AMYLOIDOSIS CENTER, 7 self-identified white patients with ATTRV122I and 19 self-identified Black patients with ATTRwt. The presentation of amyloidosis is truly diverse! Andrew Staron